Accord Healthcare's Imuldosa® Biosimilar Gets Positive Recommendation
Accord Healthcare's Imuldosa® Biosimilar Receives Positive CHMP Opinion
Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, has exciting news regarding its biosimilar product, Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®. This significant development marks a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Impact of Imuldosa® on Accord's Portfolio
This recommendation is a pivotal step for Accord as it enhances the company's growing biosimilar portfolio. With Imuldosa®, Accord solidifies its Autoimmune Franchise, building upon its existing top-selling brands. Following this addition, Imuldosa® will become the fifth biosimilar in Accord's European lineup, with ten more biosimilars currently in different stages of development.
The Importance of Ustekinumab
Ustekinumab is a human monoclonal antibody that effectively targets interleukin-12 and interleukin-23, which are crucial in managing inflammatory conditions and immune responses. The promising data surrounding Imuldosa® illustrates not only its potential for patients needing effective treatments but also its role in providing more options within the immunology market.
Statements from Accord's Executive Team
In response to this positive opinion, Paul Tredwell, Executive Vice President of Accord Healthcare, expressed his enthusiasm, stating, "We are delighted with the positive CHMP opinion for Imuldosa®. This further strengthens our established autoimmune franchise, where Accord already has several leading specialty brands. The recommendation affirms Accord's continued strategy to expand its speciality business with an industry-leading portfolio of innovative treatments. This positive opinion, alongside ten biosimilars under development, underscores our ongoing commitment to improving patient access to value-based medicines globally."
Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals Ltd, echoed this sentiment, emphasizing their dedication to enhancing global access to essential medicines through strategic partnerships and advancements in their biosimilar offerings.
Clinical Evidence Supporting the Biosimilar
The EMA CHMP's positive opinion for Imuldosa® is backed by robust clinical evidence demonstrating its similarity to the reference product, Stelara®. DMB-3115 has shown comparable quality, safety, and efficacy based on clinical trials, including a pivotal phase III multi-regional study focusing on plaque psoriasis.
The results from this trial indicate that DMB-3115 offers a similar safety and efficacy profile to Stelara®, suggesting it can serve as an effective alternative for patients requiring treatment for various immunological conditions.
The Market Landscape
Stelara®, known for its effectiveness in treating several immunology-related conditions, has amassed significant sales figures worldwide, with recent reports indicating approximately $19 billion in global revenue and around $3.2 billion in Europe alone. This robust market presence highlights the potential opportunity for Imuldosa® within the landscape of immunology treatments.
Looking Forward
With Imuldosa®'s journey toward marketing authorization progressing positively, Accord Healthcare continues to pave the way for broader access to innovative treatments for patients suffering from chronic conditions. The commitment of Accord to produce high-quality biosimilars underlines its strategic vision to meet the evolving needs of healthcare systems globally.
Frequently Asked Questions
What is Imuldosa®?
Imuldosa® is a biosimilar to Stelara® (ustekinumab), developed by Accord Healthcare, targeting immune-mediated conditions.
What does a positive CHMP opinion mean for Imuldosa®?
A positive CHMP opinion indicates that the EMA recommends marketing authorization, suggesting that the product meets necessary safety and efficacy standards.
How many biosimilars does Accord Healthcare currently have?
With the addition of Imuldosa®, Accord Healthcare will have five biosimilars in the EU market, along with ten more in development.
What is the significance of tackling interleukin-12 and interleukin-23?
Targeting these cytokines is crucial in managing inflammatory and immune responses in conditions like psoriasis and Crohn's disease.
What are the next steps for Accord Healthcare with Imuldosa®?
Accord Healthcare will continue its efforts toward finalizing marketing authorization and preparing for market launch following the positiveCHMP opinion.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Recent Proxy Voting Recommendations for Terran Orbital Merger
- State Farm Mutual Insurance Company Receives Positive Ratings Update
- AI/R Targets 2025 IPO Amidst Rapid AI Advancements
- Cross Country Healthcare's Q3 2024 Earnings Call Announcement
- Federal Budget Surplus Marks Positive Economic Shift
- Blackstone Delivers Stellar Performance, Analysts React Positively
- Acadia Healthcare's Stock Journey: From Highs to New Lows
- Northern Trust Achieves 52-Week High Following Positive Growth
- Comerica's Strong Q3 Performance Sets Positive Outlook Ahead
- Elevance Health: Analysts Adjust Targets Amidst Challenges
Recent Articles
- XRP Reversal Imminent as Bitcoin and Dogecoin See Action
- SpaceX Secures $734 Million Contract for National Security Launches
- Major Tobacco Companies Reach Landmark Settlement in Canada
- Nvidia's Future: Strong Growth Prospects in AI Market
- Utilities Soar with AI Demand: The Future of Energy Investments
- Google's Legal Victory Delays Play Store Changes Amid Controversy
- Investing Insights: Two Dow Stocks to Watch in 2025
- Verizon's Strategic Buy: $1 Billion Spectrum Deal Explained
- Calidi Biotherapeutics Faces Warrant Delisting by NYSE American
- Tevogen Bio: Pioneering Immunotherapy with Continuous Growth
- Investors Alert for WEBTOON: Class Action Details Explained
- Methode Electronics Investors Notified of Lead Plaintiff Deadline
- How Super Micro Computer Investors Can Navigate Legal Challenges
- Berkshire Hathaway Boosts Investment in Sirius XM Holdings
- Trump Considers Legal Action Against CBS Over Edited Interview
- China's Economic Strategy: Navigating Toward Stability and Growth
- China's Economic Strategies Foster Stability and Growth
- College Athletes Can Access Settlement Funds for Benefits
- Impact of Fed Interest Rates on Property Sector Dynamics
- Understanding Flux Power Holdings' Recent Challenges and Your Options
- WM Technology Faces Class Action Lawsuit: What Investors Need to Know
- Recent Proxy Voting Recommendations for Terran Orbital Merger
- Class Action Lawsuit Filed Against Xiao-I Corporation: Key Details
- Roblox Corporation Investors Urged to Explore Legal Options Now
- Edwards Lifesciences Corporation Class Action Insights
- Xiao-I Corporation Investors: Key Steps Before December Deadline
- Terran Orbital Receives Strong Support for Merger Proposal
- Sydney Beaches Reopen After Cosmetic Waste Cleanup Efforts
- Apollo Silver Expands Private Placement Offering to New Heights
- Ongoing Investigation into Winnebago Industries Sparks Claims
- Discovering High Yield Opportunities in Utilities Today
- Visa Inc. Faces Legal Scrutiny Over Alleged Misleading Practices
- Urgent Call for Orthofix Medical Inc. Shareholders to Act Now
- Critical Insights on Franklin Resources, Inc. Allegations
- Key Insights for Customers Bancorp, Inc. Investors Facing Losses
- RRCA Accounts Management Navigates Security Breach Challenges
- Is the Bull Market Nearing its Peak? Insights Ahead
- Horizon Petroleum Secures Concession Agreements in Poland
- DJI Challenges Pentagon's Military Connections Designation
- ARK Invest's Bold Moves in Biotech Stocks: Key Highlights
- mRNA Pharmaceutical Licensing Skyrockets Amid GSK Lawsuits
- Methode Electronics Faces Class Action: Investors Take Note
- Unveiling the Global Influence on U.S. Election Betting Trends
- Important Opportunities for Elanco Investors Amid Legal Action
- Toronto-Dominion Bank Faces Major Penalties for Compliance Failures
- Investigation Announced for MGP Ingredients, Inc. Shareholders
- Investigation Launched into MGP Ingredients, Inc. Amid Concerns
- Allergan Aesthetics' BOTOX® Cosmetic Expands Treatment Options
- Exploring the Collapse of Cuba's Electrical Grid and Future Prospects
- AT&T Concludes Agreement with CWA Union to Benefit Employees